基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
过继性自然杀伤(NK)细胞疗法是治疗三阴性乳腺癌的一种有前景的策略,但其疗效往往受到瘤内持久性差以及在免疫抑制性肿瘤微环境中功能耗竭的限制。
英文原题:MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer.
MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer.
这些发现表明,MUC1-C 激活 PBRM1,进而对 IFN 刺激基因进行染色质重塑,促进慢性炎症、DNA 损伤抵抗和免疫逃逸。
未标注:SWI/SNF PBAF染色质重塑复合物的染色质靶向亚基PBRM1可通过尚未明确的机制,驱动某些癌细胞产生DNA损伤耐受和免疫逃逸。STAT1和IRF1是I型和II型干扰素(IFN)通路的关键效应因子。本研究报告,MUC1-C是PBRM1表达所必需的,并且在三阴性乳腺癌(TNBC)细胞中与PBRM1形成核内复合物。全局转录组(RNA-seq)和染色质可及性(ATAC-seq)分析进一步表明,MUC1-C和PBRM1通过提高STAT1和IRF1基因启动子样特征区域的染色质可及性,促进其表达。研究还发现,MUC1-C、PBRM1和IRF1可提高II型IFN通路IDO1、WARS基因以及I型IFN通路RIG-I、MDA5、ISG15基因的表达和相应启动子样区域的染色质可及性;这些基因共同促进DNA损伤耐受和免疫逃逸。与此相符,在BRCA野生型TNBC细胞中靶向MUC1-C可增强卡铂诱导的DNA损伤,并削弱细胞自我更新能力。在奥拉帕利耐药的BRCA1突变TNBC细胞中,MUC1-C也是DNA损伤耐受、自我更新和致瘤性所必需的。TNBC肿瘤分析证实:(1)MUC1和PBRM1与化疗应答降低相关;(2)MUC1-C表达与TIL(肿瘤浸润淋巴细胞)减少相关。上述结果表明,MUC1-C可激活PBRM1,进而重塑染色质并调控IFN刺激基因,促进慢性炎症、DNA损伤耐受和免疫逃逸。意义:MUC1-C是PBRM1介导染色质重塑所必需的;这一过程可持续激活IFN通路相关基因,促进DNA损伤耐受和免疫抑制。
UNLABELLED: The polybromo-1 (PBRM1) chromatin-targeting subunit of the SWI/SNF PBAF chromatin remodeling complex drives DNA damage resistance and immune evasion in certain cancer cells through mechanisms that remain unclear. STAT1 and IRF1 are essential effectors of type I and II IFN pathways. Here, we report that MUC1-C is necessary for PBRM1 expression and that it forms a nuclear complex with PBRM1 in triple-negative breast cancer (TNBC) cells. Analysis of global transcriptional (RNA-seq) and chromatin accessibility (ATAC-seq) profiles further demonstrated that MUC1-C and PBRM1 drive STAT1 and IRF1 expression by increasing chromatin accessibility of promoter-like signatures (PLS) on their respective genes. We also found that MUC1-C, PBRM1, and IRF1 increase the expression and chromatin accessibility on PLSs of the (i) type II IFN pathway IDO1 and WARS genes and (ii) type I IFN pathway RIG-I, MDA5, and ISG15 genes that collectively contribute to DNA damage resistance and immune evasion. In support of these results, targeting MUC1-C in wild-type BRCA TNBC cells enhanced carboplatin-induced DNA damage and the loss of self-renewal capacity. In addition, MUC1-C was necessary for DNA damage resistance, self-renewal, and tumorigenicity in olaparib-resistant BRCA1-mutant TNBC cells. Analysis of TNBC tumors corroborated that (i) MUC1 and PBRM1 are associated with decreased responsiveness to chemotherapy and (ii) MUC1-C expression is associated with the depletion of tumor-infiltrating lymphocytes (TIL). These findings demonstrate that MUC1-C activates PBRM1, and thereby chromatin remodeling of IFN-stimulated genes that promote chronic inflammation, DNA damage resistance, and immune evasion. IMPLICATIONS: MUC1-C is necessary for PBRM1-driven chromatin remodeling in chronic activation of IFN pathway genes that promote DNA damage resistance and immunosuppression.
MEMBER ACCOUNT
登录成功会直接打开下一页。